GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Gross Margin %

DexCom (DexCom) Gross Margin % : 61.01% (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is DexCom Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. DexCom's Gross Profit for the three months ended in Mar. 2024 was $562 Mil. DexCom's Revenue for the three months ended in Mar. 2024 was $921 Mil. Therefore, DexCom's Gross Margin % for the quarter that ended in Mar. 2024 was 61.01%.


The historical rank and industry rank for DexCom's Gross Margin % or its related term are showing as below:

DXCM' s Gross Margin % Range Over the Past 10 Years
Min: 62.82   Med: 66.22   Max: 69.25
Current: 62.82


During the past 13 years, the highest Gross Margin % of DexCom was 69.25%. The lowest was 62.82%. And the median was 66.22%.

DXCM's Gross Margin % is ranked better than
65.08% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.575 vs DXCM: 62.82

DexCom had a gross margin of 61.01% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for DexCom was 0.10% per year.


DexCom Gross Margin % Historical Data

The historical data trend for DexCom's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Gross Margin % Chart

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.11 66.44 68.63 64.72 63.19

DexCom Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.39 62.71 63.93 63.47 61.01

Competitive Comparison of DexCom's Gross Margin %

For the Medical Devices subindustry, DexCom's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Gross Margin % distribution charts can be found below:

* The bar in red indicates where DexCom's Gross Margin % falls into.



DexCom Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

DexCom's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=2288.9 / 3622.3
=(Revenue - Cost of Goods Sold) / Revenue
=(3622.3 - 1333.4) / 3622.3
=63.19 %

DexCom's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=561.9 / 921
=(Revenue - Cost of Goods Sold) / Revenue
=(921 - 359.1) / 921
=61.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


DexCom  (NAS:DXCM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

DexCom had a gross margin of 61.01% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


DexCom Gross Margin % Related Terms

Thank you for viewing the detailed overview of DexCom's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines

From GuruFocus

Q4 2021 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024